@prefix : <http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix mp: <http://purl.org/mp/> .
@prefix oa: <http://www.w3.org/ns/oa#> .
@prefix obo: <http://purl.obolibrary.org/obo/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix core: <http://purl.obolibrary.org/obo/uberon/core#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix pato: <http://purl.obolibrary.org/obo/pato#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix core1: <http://purl.obolibrary.org/obo/core#> .
@prefix terms: <http://purl.org/dc/terms/> .
@prefix uberon: <http://purl.obolibrary.org/obo/uberon#> .
@prefix subsets: <http://purl.obolibrary.org/obo/ro/subsets#> .
@prefix oboInOwl: <http://www.geneontology.org/formats/oboInOwl#> .
@prefix OpenPVSignal: <http://purl.org/OpenPVSignal/OpenPVSignal.owl#> .
@base <http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure> .

<http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure> rdf:type owl:Ontology ;
                                                                          owl:imports <http://purl.org/OpenPVSignal/OpenPVSignal.owl> ;
                                                                          rdfs:isDefinedBy "https://apps.who.int/iris/handle/10665/255521/"^^xsd:anyURI ;
                                                                          rdfs:label "Febuxostat and Hepatic failure"^^xsd:Literal ;
                                                                          owl:versionInfo "draft-v0.95-20210611"@en .

#################################################################
#    Annotation properties
#################################################################

###  http://purl.org/dc/elements/1.1/publisher
dc:publisher rdf:type owl:AnnotationProperty .


###  http://purl.org/dc/terms/hasVersion
terms:hasVersion rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#exactMatch
skos:exactMatch rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#inScheme
skos:inScheme rdf:type owl:AnnotationProperty .


###  http://www.w3.org/2004/02/skos/core#notation
skos:notation rdf:type owl:AnnotationProperty .


#################################################################
#    Object Properties
#################################################################

###  http://purl.org/OpenPVSignal/OpenPVSignal.owl#Free_text_reporting_element
OpenPVSignal:Free_text_reporting_element rdf:type owl:ObjectProperty .


###  http://purl.org/mp/publishedBy
mp:publishedBy rdf:type owl:ObjectProperty .


###  http://purl.org/mp/references
mp:references rdf:type owl:ObjectProperty .


###  http://purl.org/mp/supportedByData
mp:supportedByData rdf:type owl:ObjectProperty .


#################################################################
#    Classes
#################################################################

###  http://www.w3.org/ns/prov#Organization
prov:Organization rdf:type owl:Class .


#################################################################
#    Individuals
#################################################################

###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dosage_for_Report_1
:Dosage_for_Report_1 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :febuxostat ;
                     <http://www.w3.org/2006/time#nominalPosition> "days" ;
                     <http://www.w3.org/2006/time#numericPosition> 15 ;
                     rdfs:label "Dosage for Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dosage_for_Report_2a
:Dosage_for_Report_2a rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Dosage ;
                      OpenPVSignal:refers_to_drug :febuxostat ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericPosition> 19 ;
                      rdfs:label "Dosage for Report 2a" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dosage_for_Report_2b
:Dosage_for_Report_2b rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Dosage ;
                      OpenPVSignal:refers_to_drug :levofloxacin ;
                      <http://www.w3.org/2006/time#nominalPosition> "days" ;
                      <http://www.w3.org/2006/time#numericPosition> 6 ;
                      rdfs:label "Dosage for Report 2b" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dosage_for_Report_3
:Dosage_for_Report_3 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :febuxostat ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 7 ;
                     rdfs:label "Dosage for Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dosage_for_Report_5
:Dosage_for_Report_5 rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Dosage ;
                     OpenPVSignal:refers_to_drug :febuxostat ;
                     <http://www.w3.org/2006/time#nominalPosition> "months" ;
                     <http://www.w3.org/2006/time#numericPosition> 3 ;
                     rdfs:label "Dosage for Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Dr_Richard_Hill
:Dr_Richard_Hill rdf:type owl:NamedIndividual ,
                          OpenPVSignal:Author ;
                 OpenPVSignal:has_affiliation "Australia" ;
                 OpenPVSignal:has_first_name "Richard" ;
                 OpenPVSignal:has_last_name "Hill" ;
                 rdfs:label "Dr Richard Hill" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration1
:Duration1 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "15 days" ;
           rdfs:label "Duration 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration2
:Duration2 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "19 days 6 days" ;
           rdfs:label "Duration 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration3
:Duration3 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "7 months" ;
           rdfs:label "Duration 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration4
:Duration4 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "unknown" ;
           rdfs:label "Duration 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration5
:Duration5 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "3 months" ;
           rdfs:label "Duration 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Duration6
:Duration6 rdf:type owl:NamedIndividual ,
                    <http://www.w3.org/2006/time#DurationDescription> ;
           OpenPVSignal:has_content "unknown" ;
           rdfs:label "Duration 6" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Febuxostat_and_Hepatic_Failure
:Febuxostat_and_Hepatic_Failure rdf:type owl:NamedIndividual ,
                                         OpenPVSignal:Pharmacovigilance_Signal_Report ;
                                OpenPVSignal:refers_to_author :Dr_Richard_Hill ;
                                OpenPVSignal:refers_to_signal :pvSignal ;
                                mp:publishedBy :uppsala_monitoring_centre ;
                                OpenPVSignal:has_creation_date "01/04/2013" ;
                                OpenPVSignal:has_overall_conclusion "causal association probable" ;
                                rdfs:label "Febuxostat and Hepatic Failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_allopurinol
:Group_from_clinical_trial_with_allopurinol rdf:type owl:NamedIndividual ,
                                                     OpenPVSignal:Cohort_Profile ;
                                            OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                            OpenPVSignal:refers_to_drug :allopurinol ;
                                            OpenPVSignal:has_count 17 ;
                                            rdfs:label "Group from clinical trial with allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_allopurinol_and_recovery
:Group_from_clinical_trial_with_allopurinol_and_recovery rdf:type owl:NamedIndividual ,
                                                                  OpenPVSignal:Cohort_Profile ;
                                                         OpenPVSignal:is_subgroup_of :Group_from_clinical_trial_with_allopurinol ;
                                                         OpenPVSignal:has_count 10 ;
                                                         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                                         rdfs:label "Group from clinical trial with allopurinol and recovery" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_febuxostat
:Group_from_clinical_trial_with_febuxostat rdf:type owl:NamedIndividual ,
                                                    OpenPVSignal:Cohort_Profile ;
                                           OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                           OpenPVSignal:refers_to_drug :febuxostat ;
                                           OpenPVSignal:has_count 57 ;
                                           rdfs:label "Group from clinical trial with febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_febuxostat_and_recovery
:Group_from_clinical_trial_with_febuxostat_and_recovery rdf:type owl:NamedIndividual ,
                                                                 OpenPVSignal:Cohort_Profile ;
                                                        OpenPVSignal:is_subgroup_of :Group_from_clinical_trial_with_febuxostat ;
                                                        OpenPVSignal:has_count 19 ;
                                                        OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                                        rdfs:label "Group from clinical trial with febuxostat and recovery" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_placebo
:Group_from_clinical_trial_with_placebo rdf:type owl:NamedIndividual ,
                                                 OpenPVSignal:Cohort_Profile ;
                                        OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                        OpenPVSignal:refers_to_drug :placebo ;
                                        OpenPVSignal:has_count 2 ;
                                        rdfs:label "Group from clinical trial with placebo" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Group_from_clinical_trial_with_placebo_and_recovery
:Group_from_clinical_trial_with_placebo_and_recovery rdf:type owl:NamedIndividual ,
                                                              OpenPVSignal:Cohort_Profile ;
                                                     OpenPVSignal:is_subgroup_of :Group_from_clinical_trial_with_placebo ;
                                                     OpenPVSignal:has_count 2 ;
                                                     OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
                                                     rdfs:label "Group from clinical trial with placebo and recovery" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#IC025ForFebuxostatAndHepaticFailure
:IC025ForFebuxostatAndHepaticFailure rdf:type owl:NamedIndividual ,
                                              <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component__025_(IC025)> ;
                                     OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
                                     OpenPVSignal:refers_to_drug :febuxostat ;
                                     OpenPVSignal:refers_to_information_component :ICForFebuxostatAndHepaticFailure ;
                                     OpenPVSignal:has_value 1.13 ;
                                     rdfs:label "IC025 for febuxostat and hepatic failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#ICForFebuxostatAndHepaticFailure
:ICForFebuxostatAndHepaticFailure rdf:type owl:NamedIndividual ,
                                           <http://purl.org/OpenPVSignal/OpenPVSignal.owl#Information_Component_(IC)> ;
                                  OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
                                  OpenPVSignal:refers_to_drug :febuxostat ;
                                  OpenPVSignal:has_value 2.5 ;
                                  rdfs:label "IC for febuxostat and hepatic failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Introduction_content
:Introduction_content rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Introduction ;
                      OpenPVSignal:has_content "Febuxostat is a xanthine oxidase inhibitor (the same mechanism of action as allopurinol) indicated for the chronic management of hyperuricaemia in patients with gout. It was approved in Europe in 2008 and in the US in 2009" ;
                      rdfs:label "Introduction content" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Literature_and_Labelling
:Literature_and_Labelling rdf:type owl:NamedIndividual ,
                                   OpenPVSignal:Literature_information ;
                          mp:references :Ref.2 ,
                                        :Ref.3 ;
                          OpenPVSignal:has_content """Hepatic failure was added to the Warnings and Precautions section of the US Product Information (PI) for febuxostat in November 2012, but has not yet been added to the UK Summary of Product Characteristics (SPC).2,3 The US PI states that liver function should be tested at baseline and on development of symptoms that may indicate liver injury, and that febuxostat should be ceased if ALT is ≥ three times ULN. However, the reports in VigiBase indicate that hepatic failure, sometimes fatal, may occur with rapid onset after starting febuxostat. The lack of reversibility of hepatic enzyme increases seen in clinical trials is also of concern.
In clinical trials of febuxostat, the incidence of alanine transaminase (ALT) ≥ three times the upper limit of normal (ULN) was 2-5% in the febuxostat groups (but not dose-related), 2% in the allopurinol group, and <1% in the placebo group.1 Reversibility of ALT and aspartate transaminase (AST) values to normal or below baseline was seen in 19/57 patients in the febuxostat groups, 10/17 for allopurinol, and 2/2 for placebo.""" ;
                          rdfs:label "Literature and Labelling" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#MechanismOfFebuxostat
:MechanismOfFebuxostat rdf:type owl:NamedIndividual ,
                                OpenPVSignal:Mechanism ;
                       OpenPVSignal:has_content "Febuxostat is a xanthine oxidase inhibitor (the same mechanism of action as allopurinol) indicated for the chronic management of hyperuricaemia in patients with gout." ;
                       rdfs:label "Mechanism of febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient1
:Patient1 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 70 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient2
:Patient2 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 83 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient3
:Patient3 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 64 ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient4
:Patient4 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_gender "male" ;
          rdfs:label "Patient 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient5
:Patient5 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 75 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Patient6
:Patient6 rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Patient ;
          OpenPVSignal:has_age 35 ;
          OpenPVSignal:has_gender "female" ;
          rdfs:label "Patient 6" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Preparations_inhibiting_uric_acid_production
:Preparations_inhibiting_uric_acid_production rdf:type owl:NamedIndividual ,
                                                       OpenPVSignal:DrugClass ;
                                              OpenPVSignal:has_ATC_code "M04AA" ;
                                              rdfs:label "Preparations inhibiting uric acid production" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Ref.1
:Ref.1 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "EMA EPAR for febuxostat (Adenuric). URL: http:// www.ema.europa.eu. Accessed: 4 January 2013." ;
       rdfs:label "Ref.1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Ref.2
:Ref.2 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "US PI for febuxostat (Uloric). URL: http://dailymed.nlm.nih.gov. Accessed: 4 January 2013." ;
       rdfs:label "Ref.2" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Ref.3
:Ref.3 rdf:type owl:NamedIndividual ,
                OpenPVSignal:Bibliographic_reference ;
       OpenPVSignal:has_content "UK SPC for febuxostat (Adenuric). URL: http://www medicines.org.uk/emc. Accessed: 4 January 2013." ;
       rdfs:label "Ref.3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report1
:Report1 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hematemesis ,
                                               :hepaticFailure ;
         OpenPVSignal:refers_to_patient :Patient1 ;
         OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_for_Report_1 ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report2
:Report2 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hepaticFailure ,
                                               :vasculitisAllergic ;
         OpenPVSignal:refers_to_patient :Patient2 ;
         OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_for_Report_2 ;
         OpenPVSignal:refers_to_secondary_suspect_drug :levofloxacin ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report3
:Report3 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hepaticFailure ,
                                               :rash ;
         OpenPVSignal:refers_to_patient :Patient3 ;
         OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_for_Report_3 ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report4
:Report4 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
         OpenPVSignal:refers_to_patient :Patient4 ;
         OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
         OpenPVSignal:refers_to_outcome_after_action "death" ;
         rdfs:label "Report 4" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report5
:Report5 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :giHaemorrhage ,
                                               :hepaticFailure ,
                                               :rash ,
                                               :renalFailure ,
                                               :thrombocytopenia ;
         OpenPVSignal:refers_to_patient :Patient5 ;
         OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
         OpenPVSignal:refers_to_reported_drug_usage :Usage_for_Report_5 ;
         OpenPVSignal:refers_to_outcome_after_action "recovery with no further information" ;
         rdfs:label "Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Report6
:Report6 rdf:type owl:NamedIndividual ,
                  OpenPVSignal:VigiBase_Report ;
         OpenPVSignal:refers_to_adverse_effect :hepaticFailure ,
                                               :renalFailureAcute ;
         OpenPVSignal:refers_to_patient :Patient6 ;
         OpenPVSignal:refers_to_outcome_after_action "unknown" ;
         rdfs:label "Report 6" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#ReportsForFebuxostatAndHepaticFailure
:ReportsForFebuxostatAndHepaticFailure rdf:type owl:NamedIndividual ,
                                                OpenPVSignal:Reports_group ;
                                       OpenPVSignal:is_subgroup_of :reportsForFebuxostat ;
                                       OpenPVSignal:is_supported_by_statistical_entity :ReportsForFebuxostatAndHepaticFailure ;
                                       OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
                                       OpenPVSignal:refers_to_drug :febuxostat ;
                                       OpenPVSignal:has_count 6 ;
                                       OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                       rdfs:label "Reports for febuxostat and Hepatic Failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Reports_in_Vigibase
:Reports_in_Vigibase rdf:type owl:NamedIndividual ,
                              OpenPVSignal:Free_text_reporting_element ;
                     mp:references :Ref.1 ;
                     OpenPVSignal:has_content """A signal for hepatic failure associated with febuxostat use was found in the WHO Global Individual Case Safety Report (ICSR) database, VigiBaseTM in October 2012 with six reports (two fatal) and IC 2.50 (IC025 1.13). Five of the reports are from the US and one from Germany. The reports are outlined in the table below:
 
As of 2 December 2012, VigiBase contained 449 reports for febuxostat, including also ten reports of hepatic function abnormal, eight reports of hepatic enzymes increased, and six reports of jaundice.""" ;
                     rdfs:label "Reports in Vigibase" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Response_from_Teijin_Pharma_Limited
:Response_from_Teijin_Pharma_Limited rdf:type owl:NamedIndividual ,
                                              OpenPVSignal:Response_to_Pharmacovigilance_Signal_Report ;
                                     OpenPVSignal:refers_to_pharmacovigilance_signal_report :Febuxostat_and_Hepatic_Failure ;
                                     OpenPVSignal:has_content """Through routine signal detection activities and periodic analysis, the Marketing Authorization Holders (Teijin Pharma Ltd in Japan, Takeda Pharmaceuticals U.S.A., Inc. in North America, and Menarini International Operations Luxembourg S.A in Europe) have identified hepatic failure (HF) as a potential signal for febuxostat. Evaluation of this signal is challenging as patients with gout often have several co-morbidities and are on several concomitant medications.
Most of collected HF reports present confounding factors, with co-morbid conditions, and other co- suspect medications. Additionally, some of these reports have insufficient information for causality assessment. Therefore current data do not allow to establish a causal relationship with febuxostat.
Evaluation of hepatic events was presented in Europe with the variation#23, where hepatitis and jaundice, but not HF, were inserted in the EU-PI. HF events were reviewed again along the PSUR#8 (up to 20-Apr-2012). The analysis indicated that a
 


causal relationship with febuxostat was confounded by alternative etiologies, co-suspect medications and co-morbidities. While two new cases (last in the below table) have been reported following the last review, these cases do not change the risk assessment or conclusion of the above mentioned review.
There have been 11 cases describing HF events. An independent expert review board (Liver safety evaluation committee, LSEC) has also analyzed the reports, key factors for all eleven ICSRs are briefly displayed in the below table.

Conclusions
Based on the careful review of hepatic events, it is not possible to establish a causal relationship and the benefit risk profile of febuxostat remains unchanged at this time. The MAHs are committed to continue close monitoring of all reported serious hepatic events. The MAHs will implement
 
appropriate actions to communicate and manage	the risk.




Age/Sex	Co-Suspect drugs	Latency	Reactions	Outcome	Medical history	Causality (Reporter)
70 Male		49 days	Hepatorenal syndrome	Fatal	Obesity, chronic alcoholism, cholelithiasis	Unlikely related, alcohol induced hepatitis
70 Male		15 days	Acute HF, oesophageal haemorrhage, nausea	Fatal	Chronic alcohol use, cholelithiasis	Not related, chronic alcohol use
69 Male	Tramadol	240 days	Acute HF	Recovered with sequelae	Cryptogenic cirrhosis, end stage CKD dyalisis, type II diabetes	Unlikely related
46 Male		390 days	Acute HF	Recovering	Alcohol abuse	Possibly related to febuxostat but acute liver decompensation while consuming an excessive amount of alcohol
83 Female	Levofloxacin	18 days	HF, leukocytoclastic vasculitis	Recovering	CRF, CHF	Related to febuxostat and levofloxacin
64 Male		7 months	HF, rash pruritic	Fatal	Hepatic funct.abnormality, CRF, alcohol consumption	Probably or possibly related
-- Male	Allopurinol	Unknown	HF	Fatal	Unknown	N/A
75 Female		77 days	HF, thrombocytopenia, renal failure, GI haemorrhage, rash	Recovered with sequelae	Gout & HTN	Not related, Alt. etiology is dehydration
35 Female		3 Weeks	HF, renal failure acute	Unknown	Unknown	N/A
83 Male	digoxin, phenprocoumon	~7 months	Acute HF, toxicity to various agent	Fatal	CRF stage IV	Unlikely related
45 Male		Unknown	HF	Unknown	Intolerant to colchicine and indocin	Not assessable""" ;
                                     rdfs:label "Response from Teijin Pharma Limited" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#US_PI_for_febuxostat_and_hepatic_failure
:US_PI_for_febuxostat_and_hepatic_failure rdf:type owl:NamedIndividual ,
                                                   obo:OAE_0001197 ,
                                                   OpenPVSignal:Structured_Product_Labels_information ,
                                                   OpenPVSignal:Warning_Information ;
                                          OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
                                          OpenPVSignal:refers_to_drug :febuxostat ;
                                          mp:references :Ref.2 ,
                                                        :Ref.3 ;
                                          OpenPVSignal:has_content "Hepatic failure was added to the Warnings and Precautions section of the US Product Information (PI) for febuxostat in November 2012, but has not yet been added to the UK Summary of Product Characteristics (SPC).2,3 The US PI states that liver function should be tested at baseline and on development of symptoms that may indicate liver injury, and that febuxostat should be ceased if ALT is ≥ three times ULN." ;
                                          rdfs:label "US PI for febuxostat and hepatic failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Usage_for_Report_1
:Usage_for_Report_1 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:refers_to_dosage :Dosage_for_Report_1 ;
                    rdfs:label "Usage for Report 1" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Usage_for_Report_2
:Usage_for_Report_2 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:refers_to_dosage :Dosage_for_Report_2a ,
                                                  :Dosage_for_Report_2b ;
                    rdfs:label "Usage for Report 2" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Usage_for_Report_3
:Usage_for_Report_3 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:refers_to_dosage :Dosage_for_Report_3 ;
                    rdfs:label "Usage for Report 3" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#Usage_for_Report_5
:Usage_for_Report_5 rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Drug_Usage ;
                    OpenPVSignal:refers_to_dosage :Dosage_for_Report_5 ;
                    rdfs:label "Usage for Report 5" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#WarningForFebuxostat
:WarningForFebuxostat rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Warning_Information ;
                      OpenPVSignal:refers_to_adverse_effect :altIncreased ,
                                                            :hepaticFailure ;
                      mp:references :Ref.2 ;
                      rdfs:label "Warning for Febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#allopurinol
:allopurinol rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Drug ;
             OpenPVSignal:hasClass :Preparations_inhibiting_uric_acid_production ;
             OpenPVSignal:has_mechanism :MechanismOfFebuxostat ;
             OpenPVSignal:has_ATC_code "M04AA01" ,
                                       "M04AA51" ;
             rdfs:label "allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#altIncreased
:altIncreased rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "R74.0" ;
              OpenPVSignal:has_MedDRA_code 10001551 ;
              OpenPVSignal:has_MedDRA_prefered_term "Alanine aminotransferase increased" ;
              rdfs:label "alt increased" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#clinicalTrialData
:clinicalTrialData rdf:type owl:NamedIndividual ,
                            obo:OAE_0001197 ,
                            OpenPVSignal:Clinical_trial_information ;
                   OpenPVSignal:refers_to_drug :allopurinol ,
                                               :febuxostat ;
                   OpenPVSignal:has_content "In clinical trials of febuxostat, the incidence of alanine transaminase (ALT) ≥ three times the upper limit of normal (ULN) was 2-5% in the febuxostat groups (but not dose-related), 2% in the allopurinol group, and <1% in the placebo group.1 Reversibility of ALT and aspartate transaminase (AST) values to normal or below baseline was seen in 19/57 patients in the febuxostat groups, 10/17 for allopurinol, and 2/2 for placebo" ;
                   rdfs:label "clinical trial data" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#febuxostat
:febuxostat rdf:type owl:NamedIndividual ,
                     OpenPVSignal:Drug ;
            OpenPVSignal:concerns_indication_for_use :gout ,
                                                     :hyperuricaemia ;
            OpenPVSignal:hasClass :Preparations_inhibiting_uric_acid_production ;
            OpenPVSignal:has_mechanism :MechanismOfFebuxostat ;
            OpenPVSignal:has_ATC_code "M04AA03" ;
            rdfs:label "febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#giHaemorrhage
:giHaemorrhage rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Adverse_Effect ;
               OpenPVSignal:has_ICD_code "K92.2" ;
               OpenPVSignal:has_MedDRA_code 10017955 ;
               OpenPVSignal:has_MedDRA_prefered_term "Gastrointestinal haemorrhage" ;
               rdfs:label "gi haemorrhage" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#gout
:gout rdf:type owl:NamedIndividual ,
               OpenPVSignal:Indication ;
      OpenPVSignal:has_ICD_code "M10" ;
      OpenPVSignal:has_MedDRA_code 10018627 ;
      OpenPVSignal:has_MedDRA_prefered_term "Gout" ;
      rdfs:label "gout" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#hematemesis
:hematemesis rdf:type owl:NamedIndividual ,
                      OpenPVSignal:Adverse_Effect ;
             OpenPVSignal:has_ICD_code "K92.0" ;
             OpenPVSignal:has_MedDRA_code 10018830 ;
             OpenPVSignal:has_MedDRA_prefered_term "Haematemesis" ;
             rdfs:label "hematemesis" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#hepaticEnzymesIncreased
:hepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10060795 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic enzyme increased" ;
                         rdfs:label "hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#hepaticFailure
:hepaticFailure rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Adverse_Effect ;
                OpenPVSignal:has_ICD_code "K72" ;
                OpenPVSignal:has_MedDRA_code 10019663 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hepatic failure" ;
                rdfs:label "hepatic failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#hepaticFunctionAbnormal
:hepaticFunctionAbnormal rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Adverse_Effect ;
                         OpenPVSignal:has_MedDRA_code 10019670 ;
                         OpenPVSignal:has_MedDRA_prefered_term "Hepatic function abnormal" ;
                         rdfs:label "hepatic function abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#hyperuricaemia
:hyperuricaemia rdf:type owl:NamedIndividual ,
                         OpenPVSignal:Indication ;
                OpenPVSignal:has_MedDRA_code 10020903 ;
                OpenPVSignal:has_MedDRA_prefered_term "Hyperuricaemia" ;
                rdfs:label "hyperuricaemia" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#jaundice
:jaundice rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Adverse_Effect ;
          OpenPVSignal:has_ICD_code "R17" ;
          OpenPVSignal:has_MedDRA_code 10023126 ;
          OpenPVSignal:has_MedDRA_prefered_term "Jaundice" ;
          rdfs:label "jaundice" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#levofloxacin
:levofloxacin rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Drug ;
              OpenPVSignal:has_ATC_code "A02BD10" ,
                                        "J01MA12" ,
                                        "J01RA05" ,
                                        "S01AE05" ;
              rdfs:label "levofloxacin" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#placebo
:placebo rdf:type owl:NamedIndividual ,
                  OpenPVSignal:Drug ;
         OpenPVSignal:has_ATC_code "V03AX10" ;
         rdfs:label "placebo" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#pvSignal
:pvSignal rdf:type owl:NamedIndividual ,
                   OpenPVSignal:Signal ;
          OpenPVSignal:Free_text_reporting_element :Introduction_content ,
                                                   :Reports_in_Vigibase ;
          OpenPVSignal:is_supported_by_individual_case_report :Report1 ,
                                                              :Report2 ,
                                                              :Report3 ,
                                                              :Report4 ,
                                                              :Report5 ,
                                                              :Report6 ;
          OpenPVSignal:is_supported_by_statistical_entity :IC025ForFebuxostatAndHepaticFailure ,
                                                          :ICForFebuxostatAndHepaticFailure ,
                                                          :ReportsForFebuxostatAndHepaticFailure ,
                                                          :reportsForFebuxostat ,
                                                          :reportsForFebuxostatAndHepaticEnzymesIncreased ,
                                                          :reportsForFebuxostatAndHepaticFunctionAbnormal ,
                                                          :reportsForFebuxostatAndJaundice ,
                                                          :reportsFromGermany ,
                                                          :reportsFromUS ,
                                                          :reportsWithFatalOutcome ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-allopurinol> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-febuxostat> ,
                                                          <http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-placebo> ;
          OpenPVSignal:refers_to_adverse_effect :hepaticFailure ;
          OpenPVSignal:refers_to_drug :febuxostat ;
          OpenPVSignal:refers_to_primary_suspect_drug :febuxostat ;
          mp:supportedByData :Group_from_clinical_trial_with_allopurinol ,
                             :Group_from_clinical_trial_with_allopurinol_and_recovery ,
                             :Group_from_clinical_trial_with_febuxostat ,
                             :Group_from_clinical_trial_with_febuxostat_and_recovery ,
                             :Group_from_clinical_trial_with_placebo ,
                             :Group_from_clinical_trial_with_placebo_and_recovery ,
                             :US_PI_for_febuxostat_and_hepatic_failure ,
                             :WarningForFebuxostat ,
                             :clinicalTrialData ;
          OpenPVSignal:initially_identified_on "01/04/2013" ;
          rdfs:label "pv signal" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#rash
:rash rdf:type owl:NamedIndividual ,
               OpenPVSignal:Adverse_Effect ;
      OpenPVSignal:has_ICD_code "R21" ;
      OpenPVSignal:has_MedDRA_code 10037844 ;
      OpenPVSignal:has_MedDRA_prefered_term "Rash" ;
      rdfs:label "rash" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#renalFailure
:renalFailure rdf:type owl:NamedIndividual ,
                       OpenPVSignal:Adverse_Effect ;
              OpenPVSignal:has_ICD_code "N18.9" ;
              OpenPVSignal:has_MedDRA_code 10038435 ;
              OpenPVSignal:has_MedDRA_prefered_term "Renal failure" ;
              rdfs:label "renal failure" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#renalFailureAcute
:renalFailureAcute rdf:type owl:NamedIndividual ,
                            OpenPVSignal:Adverse_Effect ;
                   OpenPVSignal:has_ICD_code "N17.9" ;
                   OpenPVSignal:has_MedDRA_code 10069339 ;
                   OpenPVSignal:has_MedDRA_prefered_term "Acute kidney injury" ;
                   rdfs:label "renal failure acute" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsForFebuxostat
:reportsForFebuxostat rdf:type owl:NamedIndividual ,
                               OpenPVSignal:Reports_group ;
                      OpenPVSignal:refers_to_drug :febuxostat ;
                      OpenPVSignal:has_count 449 ;
                      OpenPVSignal:refers_to_database "WHO Vigibase" ;
                      rdfs:label "reports for febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsForFebuxostatAndHepaticEnzymesIncreased
:reportsForFebuxostatAndHepaticEnzymesIncreased rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Reports_group ;
                                                OpenPVSignal:is_subgroup_of :reportsForFebuxostat ;
                                                OpenPVSignal:refers_to_adverse_effect :hepaticEnzymesIncreased ;
                                                OpenPVSignal:has_count 8 ;
                                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                rdfs:label "reports for febuxostat and hepatic enzymes increased" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsForFebuxostatAndHepaticFunctionAbnormal
:reportsForFebuxostatAndHepaticFunctionAbnormal rdf:type owl:NamedIndividual ,
                                                         OpenPVSignal:Reports_group ;
                                                OpenPVSignal:is_subgroup_of :reportsForFebuxostat ;
                                                OpenPVSignal:refers_to_adverse_effect :hepaticFunctionAbnormal ;
                                                OpenPVSignal:has_count 10 ;
                                                OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                                rdfs:label "reports for febuxostat and hepatic function abnormal" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsForFebuxostatAndJaundice
:reportsForFebuxostatAndJaundice rdf:type owl:NamedIndividual ,
                                          OpenPVSignal:Reports_group ;
                                 OpenPVSignal:is_subgroup_of :reportsForFebuxostat ;
                                 OpenPVSignal:refers_to_adverse_effect :jaundice ;
                                 OpenPVSignal:has_count 6 ;
                                 OpenPVSignal:refers_to_database "WHO Vigibase" ;
                                 rdfs:label "reports for febuxostat and jaundice" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsFromGermany
:reportsFromGermany rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Reports_group ;
                    OpenPVSignal:is_subgroup_of :ReportsForFebuxostatAndHepaticFailure ;
                    OpenPVSignal:has_count 1 ;
                    OpenPVSignal:refers_to_country "http://dbpedia.org/resource/Germany" ;
                    OpenPVSignal:refers_to_database "WHO Vigibase" ;
                    rdfs:label "reports from Germany" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsFromUS
:reportsFromUS rdf:type owl:NamedIndividual ,
                        OpenPVSignal:Reports_group ;
               OpenPVSignal:is_subgroup_of :ReportsForFebuxostatAndHepaticFailure ;
               OpenPVSignal:has_count 5 ;
               OpenPVSignal:refers_to_country "http://dbpedia.org/resource/United_States" ;
               OpenPVSignal:refers_to_database "WHO Vigibase" ;
               rdfs:label "reports from US" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#reportsWithFatalOutcome
:reportsWithFatalOutcome rdf:type owl:NamedIndividual ,
                                  OpenPVSignal:Reports_group ;
                         OpenPVSignal:is_subgroup_of :ReportsForFebuxostatAndHepaticFailure ;
                         OpenPVSignal:has_count 2 ;
                         OpenPVSignal:refers_to_database "WHO Vigibase" ;
                         rdfs:label "reports with fatal outcome" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#thrombocytopenia
:thrombocytopenia rdf:type owl:NamedIndividual ,
                           OpenPVSignal:Adverse_Effect ;
                  OpenPVSignal:has_ICD_code "D69.6" ;
                  OpenPVSignal:has_MedDRA_code 10043554 ;
                  OpenPVSignal:has_MedDRA_prefered_term "Thrombocytopenia" ;
                  rdfs:label "thrombocytopenia" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#uppsala_monitoring_centre
:uppsala_monitoring_centre rdf:type owl:NamedIndividual ,
                                    prov:Organization ;
                           rdfs:label "uppsala monitoring centre" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#vasculitisAllergic
:vasculitisAllergic rdf:type owl:NamedIndividual ,
                             OpenPVSignal:Adverse_Effect ;
                    OpenPVSignal:has_ICD_code "D69.0" ;
                    OpenPVSignal:has_MedDRA_code 10020764 ;
                    OpenPVSignal:has_MedDRA_prefered_term "Hypersensitivity vasculitis" ;
                    rdfs:label "vasculitis allergic" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-allopurinol
<http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-allopurinol> rdf:type owl:NamedIndividual ,
                                                                                                                                                            OpenPVSignal:Incidence ;
                                                                                                                                                   OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                                                                                                                                   OpenPVSignal:refers_to_drug :allopurinol ;
                                                                                                                                                   OpenPVSignal:has_value 0.02 ;
                                                                                                                                                   rdfs:label "incidence of ALT ≥ three times the upper limit of normal (ULN)-allopurinol" ,
                                                                                                                                                              "incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-allopurinol" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-febuxostat
<http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-febuxostat> rdf:type owl:NamedIndividual ,
                                                                                                                                                           OpenPVSignal:Incidence ,
                                                                                                                                                           [ rdf:type owl:Restriction ;
                                                                                                                                                             owl:onProperty OpenPVSignal:has_value ;
                                                                                                                                                             owl:someValuesFrom [ rdf:type rdfs:Datatype ;
                                                                                                                                                                                  owl:onDatatype xsd:decimal ;
                                                                                                                                                                                  owl:withRestrictions ( [ xsd:minInclusive 0.02
                                                                                                                                                                                                         ]
                                                                                                                                                                                                         [ xsd:maxInclusive 0.05
                                                                                                                                                                                                         ]
                                                                                                                                                                                                       )
                                                                                                                                                                                ]
                                                                                                                                                           ] ;
                                                                                                                                                  OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                                                                                                                                  OpenPVSignal:refers_to_drug :febuxostat ;
                                                                                                                                                  rdfs:label "incidence of ALT ≥ three times the upper limit of normal (ULN)-febuxostat" ,
                                                                                                                                                             "incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-febuxostat" .


###  http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-placebo
<http://purl.org/OpenPVSignal/Signals/2013_2_febuxostat_hepatic_failure#incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-placebo> rdf:type owl:NamedIndividual ,
                                                                                                                                                        OpenPVSignal:Incidence ,
                                                                                                                                                        [ rdf:type owl:Restriction ;
                                                                                                                                                          owl:onProperty OpenPVSignal:has_value ;
                                                                                                                                                          owl:someValuesFrom [ rdf:type rdfs:Datatype ;
                                                                                                                                                                               owl:onDatatype xsd:decimal ;
                                                                                                                                                                               owl:withRestrictions ( [ xsd:minInclusive 0
                                                                                                                                                                                                      ]
                                                                                                                                                                                                      [ xsd:maxInclusive 0.01
                                                                                                                                                                                                      ]
                                                                                                                                                                                                    )
                                                                                                                                                                             ]
                                                                                                                                                        ] ;
                                                                                                                                               OpenPVSignal:refers_to_adverse_effect :altIncreased ;
                                                                                                                                               OpenPVSignal:refers_to_drug :placebo ;
                                                                                                                                               rdfs:label "incidence of ALT ≥ three times the upper limit of normal (ULN)-placebo" ,
                                                                                                                                                          "incidenceOfALTGreaterThanThreeTimesTheUpperLimitOfNormal(ULN)-placebo" .


###  Generated by the OWL API (version 4.5.9.2019-02-01T07:24:44Z) https://github.com/owlcs/owlapi
